Member Info for Jarv55

Henrik Wareborn, chief executive of Velocys, told how the Energy Estuary - renowned for fuels production expertise and a skilled local workforce - had been a big draw.

There is also an existing direct pipeline to Heathrow Airport from near-neighbour Total Lindsey Oil Refinery, and it will be ‘plug-in ready’ for any carbon capture and storage scheme brought forward - with two schemes now emerging.

https://www.business-live.co.uk/manufacturing/500m-ba-shell-backed-jet-18279396

Chart if anyones interested
https://twitter.com/Jarvy55/status/1262385011904393219

Buy after buy https://invst.ly/qufy6
needs to clear 7

I wonder if directors will buy any more

https://youtu.be/EUWCioFT34Y last nights presenation for longs

Code 1 lol

Tells me warrants are nearly done the same happened at Ncyt and once they were finished it multibagged.

A very large majority of these are in sticky hands - over 91% - there are only 13m in free float.

https://ir.tizianalifesciences.com/stock-information/shareholder-structure

Abstract #1020, "Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort," is an independent validation of the prognostic value of StemPrintER in a cohort of more than 800 luminal ER+/HER2- postmenopausal breast cancer patients from the international TransATAC study and a head-to-head comparison of the prognostic power of StemPrintER with OncotypeDx. Results provide independent validation of StemPrintER as a potentially powerful prognostic tool to stratify patients for the risk of early or late recurrence independently of other clinicopathological parameters. Importantly, the study also shows that StemPrintER is superior to OncotypeDX in the prediction of 10-year recurrence risk in all patients, as well as in N0 and N1-3 patients. The study further demonstrates that StemPrintER is capable of outperforming OncotypeDX in providing additional prognostic information to the standard clinicopathological parameters.

Our test is better than OncotypeDX that sells at the moment for $4000 per test do the maths the revenues will be staggering here. I expect a buy out here with everything they have.

Know what you are buying research, research, research.
Innovative platform technology for oral and nasal formulations can transform the administration of Monoclonal Antibodies (‘mAbs’)Two de-risked assets in clinical evaluation that target the root causes of autoimmune/inflammatory diseases and cancerMilciclib has received ‘Orphan Drug Designation’ in US and EU for treatment of thymic carcinoma/thymoma (TC/T) Assets for unmet needs in a multi billion-dollar addressable market?NASH - $35 billion ?Crohn’s Disease - $10 billion/year by 2025?Liver cancer - $1.5 billion/year by 2022Strong intellectual property?255 patents approved and 30 pending?Covers composition of matter, process and disease indications?Oral formulation technology applicable to other mAbs therapeutics Experienced and successful biotech management teamA leverageable biotechnology platform for use in additional therapeutics

There is a $20 brokers target on this any one selling now really shouldn't be investing.

You are sat on a 5 6 bagger and you can't even see it.

Have a read of this and think about what has been added today in value.
https://www.tizianalifesciences.com/cms/resources/tlsa-investor-jan-2020.pdf

Nice seller out free to move back up

https://www.youtube.com/watch?v=16jkylVOlLs&t=25s take a listen especially to the questions at the end.

**********************HkgNOE2PBdogFZD6CchT6g telgram group just started if you want to join

Same holding for the news

updated the 31st March

this is on the website
Company information and registration
Board of Directors
Advisors
Constitutional documents
Share price
Securities information

29,571,605 Ordinary Shares in issue (noting any held as treasury shares) and, insofar as it is aware, the percentage of AIM securities that is not in public hands is 33.3%.

Identity and percentage holdings of its significant shareholders.

Last updated 31st March 2020.
Shareholder Number of Ordinary Shares Percentage of Issued Share Capital
Herald Investment Management Limited 4,031,490 13.63
Amati Global Investors Limited 3,164,557 10.70
Alto Invest 2,985,410 10.10
Cancaccord Genuity Wealth Mgmt 1,884,076 6.37
Antrak Limited 1,852,210 6.26
Gresham House 1,582,279 5.35
Bury Fitzwilliam-Lay and Partners LLP 1,459,460 4.94
Chelverton Asset Management Limited 1,225,000 4.14
The Capital for Enterprise Fund LP 889,080 3.01
Canaccord Genuity Wealth Mgmt 886,076 3.00
Director Holdings
Simon Crowther 868,475 2.94
Alyson Levett 777,796 2.63
Richard Cunningham* 1,083,100 3.66
Nigel Halkes 20,331 0.07

*this includes 7,740 shares held by Richard Cunningham’s wife